Field composites

Profile · Tirupur Knitwear Export Operator

Rajat 48 years · Export Operator · Tirupur knitwear

Runs a Tirupur knitwear export book. Tirupur's US shipments are cited above ₹15,000–16,000 crore in FY25 (Economic Times), with the US at ~35% of the town's knitwear export base (Texprocil). Apparel operating margin pre-reset was cited near 7.5% (Apparel Views). On Feb 7 2026, the US bilateral reset applied an 18% reciprocal tariff on Indian textile, leather, plastics, organic chemicals, home decor, and machinery; the prior 25% additional duty under EO 14329 terminated on the same date.

The variable Rajat is now pricing is the realised margin impact per shipment: whether the 18% reset lands as a price cut to the US buyer (margin chargeback), a price hike to the US consumer (sticky), or a chargeback line on the invoice. Layered on top: freight costs cited up approximately 40% on the Red Sea disruption (Kiaasa Red Herring Prospectus; The Loadstar), layered on top of currency drift between order and settlement. Beyond the duty itself, order migration — shipments redirected to lower-tariff supplier countries such as Bangladesh, Vietnam, and Cambodia under their own tariff schedules — does not appear in any official Indian disclosure at sector frequency.

Profile: 18% reset on the invoice · passback ambiguous · order migration to lower-tariff supplier countries not officially measured
Profile · IT-Services Chief Financial Officer (Bengaluru)

Anjali 44 years · CFO · Bengaluru IT-services

Runs the CFO function on a Bengaluru IT-services book. India's software-services exports were $190.7 Bn in FY2023-24, with the US at 54% (RBI software survey). Infosys North America revenue share was 60.1% FY2024 → 57.9% FY2025 (Infosys 20-F); HCLTech services revenue $12.4 Bn (HCLTech AR). Services are NOT goods-tariffed under EO 14257 / the Feb 7 2026 reset. The reset on Anjali's book lands somewhere else.

The impact arrives on the workforce-cost channel, not the invoice line. H.R. 6225 proposes a $100,000 employer fee for certain new H-1B petitions from FY2026; the September 2025 White House fact sheet confirms higher costs, and Axios reported officials clarified the fee would not apply to existing holders re-entering the US. The realised cost-per-billable-engineer-onsite, the global in-house centre build-out on the US client side, and the onsite-to-offshore mix recalibration move on Anjali's board pack — none of those rows are disclosed at engagement-level frequency.

Profile: goods-tariff exempt · H-1B fee on the workforce-cost channel · captive-shift not engagement-level disclosed
Profile · Pharma Contract-Manufacturing Operations Director (Hyderabad)

Vinod 52 years · Operations Director · Hyderabad pharma CDMO

Operations director on a Hyderabad pharma CDMO book. India-US pharma exports cross $10 Bn (Pharmexcil), with the US at ~32–35% of India pharma exports during FY25 (IBEF); Indian manufacturers supply ~40% of US generic volumes and ~15% of biosimilar volumes (Pharmexcil). The Feb 7 2026 reset lists generic pharma, gems / diamonds, and aircraft parts for possible reciprocal-tariff removal — subject to the successful conclusion of the Interim Agreement.

  • The carve-out is announced as a conditional. Until the Interim Agreement is concluded, the carve-out is on the headline; the realised margin remains outside it. CDMO contract value by sponsor / molecule / batch / shipment is not systematically public — Vinod's books carry the line; the announcement doesn't.
  • The conditional structure means the realised carve-out value is sensitive to a single event: the agreement landing — or not. India's pharma export ledger publishes monthly aggregate dollars; it does not publish the per-batch realised receipts after US drug-pricing pass-through, FDA / facility audit compliance cost, or the conditionality discount priced into long-tenure CDMO contracts.
  • Pre-existing context on the unconditional baseline: India pharma to the US is >95% generics, plain generics + API + formulations are 70–80% of the US-bound book; the announced carve-out lifts the headline reciprocal exposure, but the realised margin impact from US drug-pricing reform, biosimilar competition, and Chemistry-Manufacturing-and-Controls amendment timelines at the FDA is the line that sits below the carve-out itself.
Exposure announced · realised margin tied to Interim Agreement · per-batch receipts not published